Significant Medical and Surgical Morbidity in Perianal Crohn's Disease: Results from a Territory-Wide Study

Journal of Crohn's & Colitis
Wing Yan MakSiew C Ng

Abstract

The presence of perianal fistulas in Crohn's disease [CD] denotes increased disease aggressiveness. We studied the epidemiology and clinical outcomes of perianal CD [PCD] using the Hong Kong territory-wide IBD Registry [HKIBDR]. Consecutive patients with PCD were identified from the HKIBDR, and disease characteristics, treatments, and outcomes were analysed. The risks for medical and surgical therapies were assessed using Kaplan-Meier analysis. Among 981 patients with CD with 10530 patient-years of follow-up, 283 [28.8%] had perianal involvement, of which 120 [42.4%] were as first presentation. The mean age at diagnosis of PCD was 29.1 years, and 78.8% were male. The median follow-up duration was 106 months (interquartile range [IQR]: 65-161 months]. Perianal fistula [84.8%] and perianal abscess [52.7%] were the two commonest forms. Male, younger age at diagnosis of CD, and penetrating phenotypes were associated with development of PCD in multivariate analysis. Of 242 patients with fistulizing PCD, 70 [29.2%] required ≥5 courses of antibiotics, and 98 [40.5%] had ≥2 surgical procedures. Nine patients required defunctioning surgery and 4 required proctectomy. Eighty-four patients [34.7%] received biologics. Cumulative probabilit...Continue Reading

Associated Clinical Trials

References

Dec 1, 1992·International Journal of Colorectal Disease·S NordgrenL Hultén
Feb 1, 1995·Diseases of the Colon and Rectum·M PescatoriA Pera
Feb 1, 1996·Diseases of the Colon and Rectum·R F McKee, R A Keenan
Jan 1, 1996·The Australian and New Zealand Journal of Surgery·C PlatellR Woods
Mar 23, 2002·Gastroenterology·David A SchwartzWilliam J Sandborn
Nov 5, 2003·Gastroenterology·William J SandbornUNKNOWN American Gastroenterological Association Clinical Practice Committee
Jul 1, 2004·The British Journal of Surgery·B SinghB George
Mar 15, 2006·Gastroenterology·Laurent BeaugerieJacques Cosnes
Dec 8, 2007·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Michael A Kamm, Siew C Ng
Feb 27, 2010·Inflammatory Bowel Diseases·Igors IesalnieksHans J Schlitt
Feb 26, 2011·Inflammatory Bowel Diseases·Laurent Peyrin-BirouletWilliam J Sandborn
Nov 22, 2011·Journal of Gastroenterology and Hepatology·Lani PrideauxSiew C Ng
Jun 19, 2012·Diseases of the Colon and Rectum·Tim W EglintonFrank A Frizelle
Mar 26, 2013·Journal of Crohn's & Colitis·Vincent BillioudLaurent Peyrin-Biroulet
Apr 16, 2013·Gastroenterology·Siew C NgUNKNOWN Asia–Pacific Crohn's and Colitis Epidemiologic Study (ACCESS) Study Group
Jun 22, 2014·Gut·Krisztina B GecseUNKNOWN World Gastroenterology Organization International Organisation for Inflammatory Bowel Diseases IOIBD European Society of Col
Apr 18, 2015·International Journal of Surgery Case Reports·Ioannis PapaconstantinouIoannis E Koutroubakis
Jul 2, 2015·Intestinal research·Wai K Leung
May 14, 2016·Intestinal research·Wee Khoon NgSiew C Ng
Mar 30, 2017·European Journal of Gastroenterology & Hepatology·Kevin W A GöttgensStéphanie O Breukink

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.